Pharmacokinetic aspects of biotechnology products

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2184-2204

  Tang, Lisa ^a   Persky, Adam M ^b   Hochhaus, Gunther ^b   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Biotechnology; Disposition; Macromolecule drug delivery; Peptides; Pharmacokinetics; PK PD models; Proteins

Indexed keywords

ABARELIX; ADALIMUMAB; AGALSIDASE BETA; ALEFACEPT; ALEMTUZUMAB; ALTEPLASE; ASPARAGINASE; BASILIXIMAB; CETRORELIX; CYCLOSPORIN A; DACLIZUMAB; DENILEUKIN DIFTITOX; DESMOPRESSIN; DROTRECOGIN; EPTIFIBATIDE; ETANERCEPT; GANIRELIX; GLUCAGON; GOSERELIN; INFLIXIMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN BASED DRUG; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOMETRY; BIOASSAY; BIOTECHNOLOGY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INFUSION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STABILITY; DRUG TRANSPORT; ENDOCYTOSIS; EXPOSURE RESPONSE CORRELATION; FEEDBACK SYSTEM; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INJECTION; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MASS SPECTROMETRY; MODEL; NONHUMAN; PHARMACOKINETIC PHARMACODYNAMIC CORRELATION; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PREDICTION; PROTEIN DEGRADATION; RECEPTOR MEDIATED ENDOCYTOSIS; SHORT SURVEY; URINARY EXCRETION;

EID: 4344634877     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20125     Document Type: Short Survey

References (146)

1. Arlington S, Barnett S, Hughes S, Palo J. 2002. Pharma 2010: The threshold to innovation. Somers, NY: IBM Business Consulting Services.
2. DeLamarter J, Fumero S. 2002. Today's alliances for tomorrow's medicines. Drug Discov World 3, Fall:9-14.
3. Meibohm B, Derendorf H. 2002. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91:18-31.
4. CDER/FDA. 2003. Exposure response relationships: Guidance for industry. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
5. International Conference on Harmonization. 1994. ICH E4-Dose-response information to support drug registration. London: European Agency for the Evaluation of Medicinal Products.
6. Meibohm B, Derendorf H. 2003. Pharmacokinetics and pharmacodynamics of biotech drugs. In: Kayser O, Muller RH, editors. Pharmaceutical biotechnology: Drug discovery and clinical applications. Weinheim: Wiley-VCH.
7. Geary RS, Yu RZ, Levin AA. 2001. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562-573.
8. Levin AA. 1999. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69-84.
9. Shah VP, Midha KK, Findlay JW, et al. 2000. Bioanalytical method validation - A revisit with a decade of progress. Pharm Res 17:1551-1557.
10. Shah V, Midha K, Dighe S, et al. 1992. Analytical method validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J Pharmaceut Sci 81:309-312.
11. CDER/FDA. 2001. Bioanalytical method validation: Guidance for industry. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
12. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, Swanson SJ, Smith WC, Weiner RS. 2001. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm Res 18:1373-1383.
13. Mire-Sluis AR. 2001. Progress in the use of biological assays during the development of biotechnology products. Pharm Res 18:1239-1246.
14. Thorpe R, Wadhwa M, Page C, Mire-Sluis A. 1999. Bioassays for the characterisation and control of therapeutic cytokines; Determination of potency. Dev Biol Stand 97:61-71.
15. Rose MP, Gaines Das RE, Balen AH. 2000. Definition and measurement of follicle stimulating hormone. Endocr Rev 21:5-22.
16. Meager A. 2002. Biological assays for interferons. J Immunol Methods 261:21-36.
17. Sadick MD. 1999. Kinase receptor activation (KIRA): A rapid and accurate alternative to endpoint bioassays. Dev Biol Stand 97:121-133.
18. Cooper MA. 2002. Optical biosensors in drug discovery. Nat Rev Drug Discov 1:515-528.
19. Malmqvist M, Karlsson R. 1997. Biomolecular interaction analysis: Affinity biosensor technologies for functional analysis of proteins. Curr Opin Chem Biol 1:378-383.
20. Piscitelli SC, Reiss WG, Figg WD, Petros WP. 1997. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin Pharmacokinet 32:368-381.
21. Tanswell P, Modi N, Combs D, Danays T. 2002. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41:1229-1245.
22. Iacona I, Lazzarino M, Avanzini MA, Rupolo M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB. 2000. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 22:295-301.
23. Cheung W, Minton N, Gunawardena K. 2001. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418.
24. McMartin C. 1992. Pharmacokinetics of peptides and proteins: Opportunities and challenges. Adv Drug Res 22:39-106.
25. Toon S. 1996. The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21:93-103.
26. Wills RJ, Ferraiolo BL. 1992. The role of pharmacokinetics in the development of biotechnologically derived agents. Clin Pharmacokinet 23:406-414.
27. Wallis M, Gwilliam DJ, Wallis OC. 1993. Preparation and characterization of a recombinant DNA-derived ovine growth hormone variant internally labelled with sulphur-35. J Mol Endocrinol 11:351-359.
28. Wanying Q, Brodin T, Ceberg C, Ingvar C, Norrgren K, Sjogren HO, Strand SE. 1991. Radio-iodinated and internally labelled (35S) IgM monoclonal antibodies in a syngenic rat model. Acta Oncol 30:379-383.
29. Nadeau RW, Satoh H, Scheide S, Growl R, Conroy R, Garland WA, Liberato DJ. 1995. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys. Drug Metab Dispos 23:904-909.
30. Rodes G, Boppana V. 1991. Novel derivatization approaches in the analysis of peptides in biological fluids by high performance liquid chromatography. In: Garzone P, Colburn W, Mokotoff M, editors. Petides, peptoids, and proteins. Vol. 3. Cincinnati, OH: Harvey Whitney Books, pp 73-79.
31. Muller S, Hochhaus G. 1995. Metabolism of dynorphin A 1-13 in human blood and plasma. Pharm Res 12:1165-1170.
32. Muller S, Hutson A, Arya V, Hochhaus G. 1999. Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: the metabolism of dynorphin A1-13 and related fragments in human plasma. J Pharm Sci 88:938-944.
33. Feng WY, Chan KK, Covey JM. 2002. Electrospray LC-MS/MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710295) in the mouse. J Pharm Biomed Anal 28:601-612.
34. LaBella FS, Geiger JD, Glavin GB. 1985. Administered peptides inhibit the degradation of endogenous peptides. The dilemma of distinguishing direct from indirect effects. Peptides 6:645-660.
35. Nakao K, Sugawara A, Morii N, Sakamoto M, Yamada T, Itoh H, Shiono S, Saito Y, Nishimura K, Ban T, et al. 1986. The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol 31:101-103.
36. Mullis PE, Pal BR, Matthews DR, Hindmarsh PC, Phillips PE, Dunger DB. 1992. Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus. Clin Endocrinol (Oxf) 36:255-263.
37. Fasano A. 1998. Novel approaches for oral delivery of macromolecules. J Pharm Sci 87:1351-1356.
38. Mahato RI, Narang AS, Thoma L, Miller DD. 2003. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153-214.
39. Lan LB, Dalton JT, Schuetz EG. 2000. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58:863-869.
40. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
41. Handelsman DJ, Swerdloff RS. 1986. Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr Rev 7:95-105.
42. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. 1998. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578-583.
43. Porter CJ, Charman SA. 2000. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297-310.
44. Supersaxo A, Hein W, Gallati H, Steffen H. 1988. Recombinant human interferon alpha-2a: Delivery to lymphoid tissue by selected modes of application. Pharm Res 5:472-476.
45. Supersaxo A, Hein WR, Steifen H. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-169.
46. Schomburg A, Kirchner H, Atzpodien J. 1993. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: Evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 119:745-755.
47. Laube BL. 2001. Treating diabetes with aerosolized insulin. Chest 120:998-1068.
48. Cleland JL, Daugherty A, Mrsny R. 2001. Emerging protein delivery methods. Curr Opin Biotechnol 12:212-219.
49. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA. 2001. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134:203-207.
50. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. 2001. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139:813-820.
51. Zito SW. 1997. Pharmaceutical biotechnology: A programmed text. Lancaster, PA: Technomic Pub. Co.
52. Harris AS. 1993. Review: Clinical opportunities provided by the nasal administration of peptides. J Drug Target 1:101-116.
53. Lawrence D. 2002. Intranasal delivery could be used to administer drugs directly to the brain. Lancet 359:1674.
54. Thorne RG, Lagalwar S, Rahman YE, Frey WH II. 1999. Intranasal adminstration of insulin-like growth factor-1 (IGF-1): A noninvasive CNS-drug delivery strategy for bypassing the blood-brain barrier. Growth Horm IGF Res 9:387.
55. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd. 2001. Intranasal administration of insulin-like growth factor-I bypasses the bloodbrain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187:91-97.
56. Mitragotri S, Blankschtein D, Langer R. 1995. Ultrasound-mediated transdermal protein delivery. Science 269:850-853.
57. Kanikkannan N. 2002. Iontophoresis-based transdermal delivery systems. BioDrugs 16:339-347.
58. Pillai O, Panchagnula R. 2003. Transdermal iontophoresis of insulin. V. Effect of terpenes. J Controlled Release 88:287-296.
59. Kumar S, Char H, Patel S, Piemontese D, Iqbal K, Malick AW, Neugroschel E, Behl CR. 1992. Effect of iontophoresis on in vitro skin permeation of an analogue of growth hormone releasing factor in the hairless guinea pig model. J Pharm Sci 81:635-639.
60. Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. 2000. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 200:107-113.
61. Suzuki Y, Iga K, Yanai S, Matsumoto Y, Kawase M, Fukuda T, Adachi H, Higo N, Ogawa Y. 2001. Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34). J Pharm Pharmacol 53:1227-1234.
62. Shen WC. 2003. Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 8:607-608.
63. Lee HJ. 2002. Protein drug oral delivery: The recent progress. Arch Pharm Res 25:572-584.
64. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, Chou J, McDonough J, Baughman RA. 2001. Oral delivery of biologically active parathyroid hormone. Pharm Res 18:964-970.
65. Joseph JW, Kalitsky J, St-Pierre S, Brubaker PL. 2000. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 43:1319-1328.
66. Pauletti GM, Gangwar S, Siahaan TJ, Jeffrey A, Borchardt RT. 1997. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27:235-256.
67. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. 2002. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603-608.
68. Working P, Cossum P. 1991. Clinical and preclinical studies with recombinant human proteins: Effect of antibody production. In: Garzone P, Colburn W, Mokotoff M, editors. Petides, peptoids, and proteins. Vol. 3. Cincinnati, OH: Harvey Whitney Books, pp 158-168.
69. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P. 2001. Interferon-beta (INF-beta) antibodies in interferon-betala- and interferon-betalb-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56-61.
70. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
71. Molineux G. 2003. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23:3S-8S.
72. Walsh S, Shah A, Mond J. 2003. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 47:554-558.
73. Graham ML. 2003. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 55:1293-1302.
74. Zamboni WC. 2003. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23:9S-14S.
75. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. 1995. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 28:126-142.
76. Tan AC, Russel FG, Thien T, Benraad TJ. 1993. Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 24:28-45.
77. Colburn W. 1991. Peptide, peptoid, and protein pharmacokinetics/ pharmacodynamics. In: Garzone P, Colburn W, Mokotoff M, editors. Petides, peptoids, and proteins. Vol. 3. Cincinnati, OH: Harvey Whitney Books, pp 94-115.
78. Periti P, Mazzei T, Mini E. 2002. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 41:485-504.
79. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC. 1999. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66:246-257.
80. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, Yoshimoto R. 2002. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 22:187-192.
81. Braeckman R. 1997. Pharmacokinetics and pharmacodynamics of peptide and protein drugs. In: Crommelin D, Sindelar R, editors. Pharmaceutical biotechnology. Amsterdam: Harwood Academic Publishers, pp 101-122.
82. Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE. 1998. Disposition of 14Ceptifibatide after intravenous administration to healthy men. Clin Ther 20:307-323.
83. Chanson P, Timsit J, Harris AG. 1993. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25:375-391.
84. Veng-Pedersen P, Gillespie W. 1984. Mean residence time in peripheral tissue: A linear disposition parameter useful for evaluating a drug's tissue distribution. J Pharmacokinet Biopharm 12:535-543.
85. Straughn AB. 1982. Model-independent steady-state volume of distribution. J Pharm Sci 71:597-598.
86. Perrier D, Mayersohn M. 1982. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71:372-373.
87. Mohler M, Cook J, Lewis D, Moore J, Sinicropi D, Championsmith A, Ferraiolo B, Mordenti J. 1993. Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metab Dispos 21:71-75.
88. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. 2002. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72:20-32.
89. Li H, Sun H, Qian ZM. 2002. The role of the transferrin-transferrin- receptor system in drug delivery and targeting. Trends Pharmacol Sci 23:206-209.
90. Wu D, Song BW, Vinters HV, Pardridge WM. 2002. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target 10:239-245.
91. Pardridge WM, Kang YS, Buciak JL. 1994. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res 11:738-746.
92. Meissner HC, Groothuis JR, Rodriguez WJ, et al. 1999. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother 43:1183-1188.
93. Paik SH, Betti F, Camargo AC, de Oliveira ES. 1992. Presence of endo-oligopeptidase (EC 3.4.22.19), a putative neuropeptide-metabolizing endopeptidase in cells of the immune system. J Neuroimmunol 38:35-44.
94. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. 1979. Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney Int 16:251-270.
95. Anderson PM, Sorenson MA. 1994. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 27:19-31.
96. Takagi A, Masuda H, Takakura Y, Hashida M. 1995. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J Pharmacol Exp Ther 275:537-543.
97. Johnson V, Maack T. 1977. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am J Physiol 233:F185-F196.
98. Rabkin R, Ryan MP, Duckworth WC. 1984. The renal metabolism of insulin. Diabetologia 27:351-357.
99. Edwards A, Daniels BS, Deen WM. 1999. Ultrastructural model for size selectivity in glomerular filtration. Am J Physiol 276:F892-F902.
100. Oliver JD 3rd, Anderson S, Troy JL, Brenner BM, Deen WH. 1992. Determination of glomerular size-selectivity in the normal rat with Ficoll. J Am Soc Nephrol 3:214-228.
101. Deen WM, Lazzara MJ, Myers BD. 2001. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281:F579-F596.
102. Carone FA, Peterson DR. 1980. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 238:F151-F158.
103. Carone FA, Peterson DR, Flouret G. 1982. Renal tubular processing of small peptide hormones. J Lab Clin Med 100:1-14.
104. Inui K, Terada T, Masuda S, Saito H. 2000. Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol Dial Transplant 15(Suppl 6):11-13.
105. Daniel H, Herget M. 1997. Cellular and molecular mechanisms of renal peptide transport. Am J Physiol 273:F1-F8.
106. Krogsgaard Thomsen M, Friis C, Sehested Hansen B, Johansen P, Eschen C, Nowak J, Poulsen K. 1994. Studies on the renal kinetics of growth hormone (GH) and on the GH receptor and related effects in animals. J Pediatr Endocrinol 7:93-105.
107. Nielsen S, Nielsen JT, Christensen EI. 1987. Luminal and basolateral uptake of insulin in isolated, perfused, proximal tubules. Am J Physiol 253:F857-F867.
108. Groves CE, Morales M, Wright SH. 1998. Peritubular transport of ochratoxin A in rabbit renal proximal tubules. J Pharmacol Exp Ther 284:943-948.
109. Authier F, Posner BI, Bergeron JJ. 1996. Endosomal proteolysis of internalized proteins. FEBS Lett 389:55-60.
110. Smedsrod B, Einarsson M. 1990. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb Haemost 63:60-66.
111. Authier F, Danielsen GM, Kouach M, Briand G, Chauvet G. 2001. Identification of insulin domains important for binding to and degradation by endosomal acidic insulinase. Endocrinology 142:276-2789.
112. Authier F, Metioui M, Fabrega S, Kouach M, Briand G. 2002. Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. J Biol Chem 277:9437-9446.
113. Authier F, Mort JS, Bell AW, Posner BI, Bergeron JJ. 1995. Proteolysis of glucagon within hepatic endosomes by membrane-associated cathepsins B and D. J Biol Chem 270:15798-15807.
114. Bu G, Williams S, Strickland DK, Schwartz AL. 1992. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 89:7427-7431.
115. Levy G. 1994. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
116. Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W. 1997. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 62:675-690.
117. Schulman ES. 2001. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Grit Care Med 164:S6-S11.
118. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. 1996. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279:1000-1008.
119. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T, Tajima T. 1999. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81:1419-1425.
120. Kobayashi H, Shirakawa K, Kawamoto S, et al. 2002. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(lB4M-Gd)(256). Cancer Res 62:860-866.
121. Murakami T, Misaki M, Masuda S, Higashi Y, Fuwa T, Yata N. 1994. Dose-dependent plasma clearance of human epidermal growth factor in rats. J Pharm Sci 83:1400-1403.
122. Kuwabara T, Uchimura T, Kobayashi H, Kobayashi S, Sugiyama Y. 1995. Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am J Physiol 269:E1-E9.
123. Kuwabara T, Uchimura T, Takai K, Kobayashi H, Kobayashi S, Sugiyama Y. 1995. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. J Pharmacol Exp Ther 273:1114-1122.
124. Mahmood I, Balian JD. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 36:1-11.
125. Mahmood I. 2002. Interspecies scaling: Predicting oral clearance in humans. Am J Ther 9:35-42.
126. Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
127. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
128. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
129. Mahmood I. 2004. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 93:177-185.
130. Meibohm B, Derendorf H. 1997. Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401-413.
131. Derendorf H, Meibohm B. 1999. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives. Pharm Res 16:176-185.
132. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P. 1997. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142-152.
133. Breimer DD, Danhof M. 1997. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm. Clin Pharmacokinet 32:259-267.
134. Lesko LJ, Rowland M, Peck CC, Blaschke TF. 2000. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol 40:803-814.
135. Levy G. 1994. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56:356-358.
136. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ. 1998. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15:1895-1901.
137. Gaussem P, Dubar M, le Bonniec B, Richard-Lordereau I, Jochemsen R, Aiach M. 2002. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects. Br J Clin Pharmacol 53:147-154.
138. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. 1999. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291:1060-1067.
139. Sun YN, Lee HJ, Almon RR, Jusko WJ. 1999. A pharmacokinetic/ pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J Pharmacol Exp Ther 289:1523-1532.
140. Bressolle F, Audran M, Gareau R, Pham TN, Gomeni R. 1997. Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes. J Pharmacokinet Biopharm 25:263-275.
141. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. 2000. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 292:810-816.
142. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. 2002. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 71:235-245.
143. Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, Derendorf H. 2000. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol 40:266-274.
144. Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, Sheiner LB. 1996. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol 271:E775-E787.
145. Hosseini M, Nagels K, Furth J, Muller M. 2001. Driving bio deals. SCRIP Magazine, December, 22-25.
146. Nagle T, Berg C, Nassr R, Pang K. 2003. The further evolution of biotech. Nat Rev Drug Discov 2:75-79.